EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity

Hanchen Zhao, Tyler S Beyett iD, Jie Jiang, Jaimin K Rana, Ilse K Schaeffner, Jhasmer Santana, Pasi A Jänne, Michael J Eck iD

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2417144121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Hanchen Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215. Hauptthemen laut MEDLINE: ErbB Receptors, Exons, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Cancer Institute (NCI), NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Somatic mutations in the epidermal growth factor receptor (EGFR) are a major cause of non–small cell lung cancer. Among these structurally diverse alterations, exon 20 insertions represent a unique subset that rarely respond to EGFR tyrosine kinase inhibitors (TKIs). Therefore, there is a significant need to develop inhibitors that are active against this class of activating mutations. Here, we conducted biochemical analysis of the two most frequent exon 20 insertion variants, V769_D770insASV (insASV) and D770_N771insSVD (insSVD) to better understand their drug sensitivity and resistance. From kinetic studies, we found that EGFR insASV and insSVD are similarly active, but have lower K m, ATP values compared to the L858R variant, which contributes to their lack of sensitivity to 1st-3rd generation EGFR TKIs. Biochemical, structural, and cellular studies of a diverse panel of EGFR inhibitors revealed that the more recently developed compounds BAY-568, TAS6417, and TAK-788 inhibit EGFR insASV and insSVD in a mutant-selective manner, with BAY-568 being the most potent and selective versus wild-type (WT) EGFR. Cocrystal structures with WT EGFR reveal the binding modes of each of these inhibitors and of poziotinib, a potent but not mutantselective inhibitor, and together they define interactions shared by the mutant-selective agents. Collectively, our results show that these exon20 insertion variants are not inherently inhibitor resistant, rather they differ in their drug sensitivity from WT EGFR. However, they are similar to each other, indicating that a single inhibitor should be effective for several of the diverse exon 20 insertion variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsExonsProtein Kinase InhibitorsHumansCarcinoma, Non-Small-Cell LungMutagenesis, InsertionalLung NeoplasmsDrug Resistance, Neoplasm

Stichwörter der Autor:innen

EGFR inhibitorsX-ray crystallographyenzymologylung cancer

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
  • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115.
  • Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
  • Department of Medicine, Harvard Medical School, Boston, MA 02115.

ORCID-Profile: Tyler S Beyett, Michael J Eck

Förderung

  • HHS | NIH | National Cancer Institute (NCI)
  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIH HHS

Zitieren

APA

Zhao, H., Beyett, T. S., Jiang, J., Rana, J. K., Schaeffner, I. K., Santana, J., Jänne, P. A., & Eck, M. J. (2024). Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2417144121

Vancouver

Zhao H, Beyett TS, Jiang J, Rana JK, Schaeffner IK, Santana J, et al. Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2417144121

BibTeX
@article{Zhao2024,
  author = {Zhao, Hanchen and Beyett, Tyler S and Jiang, Jie and Rana, Jaimin K and Schaeffner, Ilse K and Santana, Jhasmer and Jänne, Pasi A and Eck, Michael J},
  title = {Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2417144121}
}
Kostenlos starten →